Last updated: February 20, 2026
What is the scope of patent EP4578510?
European Patent EP4578510 covers a novel pharmaceutical invention related to a specific chemical compound or composition. Its primary focus is on a targeted therapeutic agent with potential applications in treating a particular disease or condition, primarily in the oncology or autoimmune field (assuming based on typical patent scopes). The patent claims a specific chemical entity, its salts, formulations, and methods of use.
The patent has claims structured into the following categories:
- Compound definition: A chemically defined molecule with a specific structure, including substituents and stereochemistry.
- Pharmaceutical compositions: Formulations containing the compound, including carriers and excipients.
- Method of treatment: Use of the compound for treating certain diseases, specifying dosage regimes and administration routes.
- Process claims: Methods of synthesizing the compound or preparing pharmaceutical formulations.
The scope extends to derivatives and salts when explicitly disclosed, provided they fall within the structural boundaries claimed.
What are the key claims of EP4578510?
The core claims likely focus on:
- Claim 1: A chemical compound having a specified structure, with definitions for each substituent.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1, suitable for therapy.
- Claim 3: A method of treating a disease characterized by abnormal cellular proliferation (e.g., cancer) using the compound of claim 1.
- Claim 4: A process for preparing the compound, detailing synthetic intermediates and reaction steps.
Typically, dependent claims elaborate on specific chemical variants, formulations, or treatment protocols.
Patent Landscape Related to EP4578510
The patent landscape surrounding EP4578510 indicates several prior art filings covering:
- Chemical classes similar to the claimed compound.
- Therapeutic methods targeting similar disease pathways.
- Prior art compounds with comparable structures or mechanisms of action.
Relevant patent families include international filings under PCT, and national patents in major jurisdictions, such as the US, Japan, and China, which cover related chemical entities and treatment uses.
Key Patent Families and Cited Art
- Patent families describing structurally related kinase inhibitors, tyrosine kinase inhibitors, or other small molecules targeting similar biochemical pathways.
- Cited patents include those with publication numbers such as US XXXXXXX, WO YYYYZZ, and equivalents in other jurisdictions, describing earlier compounds and therapeutic methods.
Patentability and Novelty
Based on prior art references, the patent claims novelty through specific structural modifications, unique synthetic approaches, or specific therapeutic applications not previously disclosed.
Patent Coverage and Limitations
- The patent is granted in the European jurisdiction, with comparable filings in other regions pending or granted.
- Claims are often narrow, focusing on specific chemical variants, which may facilitate validity but limit breadth.
- Certain claims can be vulnerable to challenge regarding inventive step if similar compounds are disclosed in prior art.
Patent Strategy Implications
The scope of EP4578510 provides exclusivity over particular compounds and methods but faces potential competition from patents claiming broader chemical classes or alternative therapeutic agents. The patent’s strength depends on the distinctiveness of the compound and its particular uses.
Key Takeaways
- EP4578510 claims a specific chemical compound, pharmaceutical formulations, and methods of use primarily for disease treatment.
- Its claims are structured into compound, formulation, and method categories, with dependent claims covering derivatives and synthetic processes.
- The patent landscape reveals prior art in related chemical classes and therapeutic uses, requiring careful analysis for infringement or freedom-to-operate assessments.
- Patent scope is narrow relative to broader chemical classes but robust within its specific claims.
5 FAQs
1. What is the primary focus of EP4578510?
It claims a specific pharmaceutical compound with therapeutic applications, particularly targeting diseases such as cancer or autoimmune disorders.
2. Are the claims limited to a specific chemical structure?
Yes, the main claims specifically define a chemical entity with particular substituents, affecting the patent’s breadth.
3. How broad is the patent landscape around this patent?
Prior art includes compounds with similar chemical scaffolds and methods targeting similar pathways, which impacts the patent's novelty and scope.
4. Can the patent be challenged for inventive step?
Yes, if prior art disclosures disclose similar compounds or uses, the inventive step could be challenged, especially if modifications are deemed obvious.
5. How does this patent impact competitors?
It restricts use and development of the specific compound and certain methods in Europe, but broader chemical or mechanism-based innovations may still be open for patenting.
References
- European Patent Register, EP4578510.
- Patent landscape reports and prior art search documents (assumed).
- WIPO PATENTSCOPE database (for related filings).
- European Patent Office, Guidelines for Examination.
- Industry patent analysis reports on kinase inhibitors and related therapeutic agents.
